Gujarat Terce Laboratories
37.50
-0.50(-1.32%)
Market Cap₹29.21 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D-1.32%
1M-9.22%
6M-6.25%
1Y-47.55%
5Y+400.67%
View Company Insightsright
More news about Gujarat Terce Laboratories
11Aug 25
Gujarat Terce Laboratories Reports Q1 Loss, Reshuffles Board Committees
Gujarat Terce Laboratories Limited reported a net loss of Rs 4.35 lakhs for Q1, an improvement from Rs 7.76 lakhs loss in the previous year. Revenue decreased to Rs 1,085.36 lakhs from Rs 1,188.88 lakhs. The company reconstituted its Audit, Nomination and Remuneration, and Stakeholders' Relationship Committees. Statutory auditors provided an unmodified opinion on the quarterly results.
 no imag found
26Jul 25
Gujarat Terce Laboratories Reports Net Loss Despite Revenue Growth, Settles Tax Disputes
Gujarat Terce Laboratories Limited reported a 3.93% increase in total revenue to ₹50.20 crore, with sales rising 4.58% to ₹50.20 crore. EBITDA surged 143.12% to ₹3.89 crore, improving the EBITDA margin from 3.31% to 7.75%. However, the company faced a net loss of ₹0.98 crore due to a one-time tax settlement provision of ₹3.42 crore. The company reduced its debt-to-equity ratio from 0.54 to 0.15 and achieved zero borrowing in Q4. Operational improvements included better inventory and receivables management.
 no imag found
1 Year Returns:-47.55%
Industry Peers
Sun Pharmaceutical
1,801.60
(-1.30%)
Divis Laboratories
6,071.00
(-3.36%)
Torrent Pharmaceuticals
4,390.00
(-1.26%)
Dr Reddys Laboratories
1,292.30
(-2.02%)
Cipla
1,314.70
(-0.72%)
Lupin
2,314.90
(-1.80%)
Zydus Life Science
905.90
(-1.20%)
Mankind Pharma
2,138.90
(-3.13%)
Aurobindo Pharma
1,296.50
(-1.17%)
Alkem Laboratories
5,355.50
(-1.63%)